Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration (NCT00423189), a randomized phase 4 study. The primary outcome is Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of >15 Letters at 12 Months).

2. Clinical Question

The clinical question is whether adding reduced-fluence PDT to intravitreal ranibizumab is associated with a different frequency of the stated visual-acuity outcome than ranibizumab alone. The trial is described as a Phase IV comparative study in people with exudative AMD. Its registry record identifies random allocation and a parallel-group model, but does not report how the allocation sequence was generated or concealed.

The primary outcome is not a continuous comparison of average letter change. It is a count of participants meeting the titled threshold for visual-acuity gain or loss. The posted values are zero in each listed arm. That is a descriptive result for this registry record; it does not establish whether the treatment strategies differ in the wider population. The small enrollment and absence of a reported comparative analysis leave substantial uncertainty. The registry record does not provide estimates of treatment effects or confidence intervals for this endpoint.

3. Trial Design

The registry describes the LUV Trial as a Phase IV, randomized, parallel-group study with no masking. It compares intravitreal ranibizumab alone with ranibizumab combined with verteporfin photodynamic therapy at reduced fluence. The combination groups are labeled 40% fluence PDT/ranibizumab and 20% fluence PDT/ranibizumab; the ranibizumab-only group is the comparator. The summary characterizes the target population as patients with exudative age-related macular degeneration.

The record lists enrollment as 7. It records a start of 2007-01, primary completion of 2009-01, and a status of terminated. A reason for termination is not reported in the registry record, so the status alone does not explain why the study ended or whether the planned follow-up was completed for every participant. The registry identifies David M. Brown, M.D. as sponsor.

Masking is listed as none. The record does not describe whether outcome assessors were kept unaware of treatment assignment, nor does it give details of randomization procedures, allocation concealment, treatment delivery, or deviations from assigned treatment. Those details should not be inferred from the labels “randomized” and “none.”

The intervention listings name ranibizumab (Lucentis) and 0.5mg ranibizumab, while the arm descriptions specify intravitreal ranibizumab and the PDT combinations. The registry lists secondary outcomes relating to ranibizumab injection counts, macular thickness by OCT, choroidal perfusion assessed by ICG angiography, and safety. Their stated follow-up points include assessments through 12 months. The registry record does not provide posted numerical results for those secondary outcomes in the registry record described for this analysis.

The record gives no protocol details, eligibility criteria beyond the broad disease description, or explanation of the planned sample size. It also does not report the statistical analysis plan. Those omissions limit assessment of how closely the reported outcome data align with the intended design.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: patients that were considered to have recalcitrant wet age related macular degeneration were recruited for this trial

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: As per subjects participated

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of >15 Letters at 12 Months), measured over 1 Year.

The primary endpoint is titled as best-corrected ETDRS visual acuity at 6 months and 12 months, with the event defined as a gain or loss of >15 letters at 12 months. ETDRS testing is a standardized way to assess visual acuity using a letter chart. A threshold-based outcome turns letter change into a binary classification: a participant either meets the specified gain-or-loss criterion or does not. The registry records the outcome as a number of participants.

The outcome description clarifies an important mismatch in timing: visual acuity was measured by ETDRS at 12 months by certified refractionists in certified lanes, but was not measured by ETDRS at 6 months. Therefore, the posted primary result addresses the 12-month threshold outcome, not a measured 6-month ETDRS result. The timeframe is also described as 1 Year.

A threshold outcome can make a clinically interpretable change easier to count, while discarding information about the size and direction of changes that do not cross the threshold. The registry record does not report the underlying letter-change distributions, separate counts for gains and losses, or a more detailed definition of how those directions are combined. The posted values are zero for the listed groups. They should be read as counts for the recorded endpoint, not as evidence that visual acuity was unchanged for every participant.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

General statistical explanation: the endpoint is binary because it classifies participants according to whether they meet the specified gain-or-loss threshold. A binary outcome is commonly summarized by event counts and the number of participants assessed. Here, the registry lists zero events in each treatment group and gives group sizes of 2, 3, and 2. Those are the posted counts, not a basis for inferring a precise population-level rate.

What does a confidence interval add?

In general, a confidence interval expresses the uncertainty around an estimated treatment effect. It indicates which effect sizes are reasonably compatible with the observed data under the method used. With very small groups and no observed events, estimates can be especially imprecise; a zero count does not mean that the true event probability is known to be zero. The registry record does not report confidence intervals or another uncertainty interval for the primary comparison.

For this particular endpoint, the record reports counts but no treatment-effect estimate. Since all three groups have zero recorded events, a comparison based on the posted binary results is not estimable in the manner indicated by the record. No effect estimate should be reconstructed from these counts. The record marks the comparison as unavailable because values are missing or not estimable for a two-arm comparison of the binary endpoint. The sponsor's own analysis does not take precedence on the basis of a reported discrepancy; the record indicates no discrepancy.

Why can sparse outcomes be difficult to compare?

General statistical explanation: when events are rare or absent in small groups, standard approximations can perform poorly, and estimated effects may be unstable or undefined. Methods for sparse binary data may use exact calculations or models designed for rare events, but the appropriate approach depends on the study design and analysis plan. The registry record does not identify a method used for a formal primary-outcome comparison. The stated normal approximation relates to planning illustrations, not to a reported analysis of the trial outcome.

The study includes a ranibizumab-only group and two combination groups, but the registry's comparison note specifically addresses a two-arm comparison. It does not explain which pairwise comparison was intended for that calculation, whether all groups were to be compared, or how a multi-group question would be handled. The statistical analysis plan and any prespecified contrasts are not reported in the registry record. No unreported contrast or test should be assumed.

How should planning calculations be understood?

The registry describes sample-size illustrations based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is expressed as a stated fraction of the observed effect. These are planning assumptions, not a description of the trial's original sample-size justification. The rationale for the actual enrollment is not reported in the registry record.

Such illustrations answer a hypothetical design question: under the stated assumptions, how many participants per arm might be needed for a chosen power to detect an effect of a specified size? They do not indicate the probability that the completed trial found a true effect, and they are never observed power. Estimates based on an observed effect can also be unstable when the source trial has very sparse data or no estimable contrast. The listed assumptions do not change the fact that the trial's posted primary counts are zero in each arm and that no comparative analysis is reported.

What is over-dispersion, and does it apply?

General statistical explanation: over-dispersion occurs when observed variability is greater than a statistical model expects. It matters because standard errors may then be too small, making intervals look too narrow and tests too optimistic. Over-dispersion is usually discussed for outcomes or models with repeated counts or clustered variation. The primary outcome is a participant-level binary count, and the registry does not report a model in which over-dispersion was assessed. It should not be asserted as a feature of this trial's analysis.

The secondary outcomes include injection counts, OCT macular thickness, choroidal perfusion assessed by ICG angiography, and safety. Different outcome types may require different statistical summaries and assumptions. For example, repeated measurements over time require attention to within-participant dependence, while event counts may require methods suited to count distributions. These are general considerations only; the registry record does not state the models, tests, covariance assumptions, or multiplicity procedures used for these outcomes.

What does the analysis record establish?

The registry lists zero analyses. It provides the primary outcome counts and group sizes, but no model estimates, standard errors, confidence intervals, p-values, or adjustment details. The recorded population phrase, “As per subjects participated,” does not identify how participants were handled if they missed assessments, withdrew, or deviated from assigned treatment. The record also does not report an interim analysis plan, endpoint adjudication process, or a statistical analysis plan. These omissions prevent a fuller assessment of the inferential methods and the extent to which analyses were prespecified.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Ranibizumab Only", "40% Fluence PDT/Ranibizumab", "20% Fluence PDT/Ranibizumab")
n      <- c(2, 3, 2)
events <- c(0, 0, 0)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Ranibizumab Only  2  0  0.0  0.0  84.2  0.0  65.8  0.8  70.8
ARM  40% Fluence PDT/Ranibizumab  3  0  0.0  0.0  70.8  0.0  56.1  0.6  60.2
ARM  20% Fluence PDT/Ranibizumab  2  0  0.0  0.0  84.2  0.0  65.8  0.8  70.8

11. Multiplicity, Missing Data and Analysis Populations

The registry lists four secondary outcomes: ranibizumab injection counts at 12 months, OCT macular thickness improvement at the stated assessment times, choroidal perfusion assessed by ICG angiography at the stated assessment times, and safety of the combination therapy. The record also lists five outcome measures overall. It does not report whether a hierarchy, adjustment, or other multiplicity strategy was prespecified for testing several outcomes or time points. The number of analyses is listed as 0, so no family of reported statistical tests can be evaluated from this record.

When many outcomes or time points are examined, the chance of at least one apparently unusual result can increase. General statistical practice may address this through prespecified primary outcomes, hierarchical testing, or adjustments, but none should be attributed to this trial without documentation. The primary outcome itself has a timing discrepancy: its title mentions 6 and 12 months, while its description says ETDRS visual acuity was not measured at 6 months.

Missing-data handling is not reported in the registry record. There is no account of participants without a 12-month assessment, reasons for missing measurements, imputation, or sensitivity analyses. The listed outcome population, “As per subjects participated,” does not specify an established analysis set. The registry does not say whether all randomized participants were included in the primary analysis or how departures from assigned treatment were addressed. These gaps limit assessment of whether the posted counts represent the intended analysis population and whether missingness could affect interpretation.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: death of unknown origin (33.3%).

The registry reports serious adverse event figures by group. For Ranibizumab Only, 0 of 2 at-risk participants were affected; for 40% Fluence PDT Combined With Ranibizumab, 1 of 3 were affected; and for 20% PDT Fluence Combined With Ranibizumab, 0 of 2 were affected. These are descriptive registry counts. They do not, by themselves, establish that treatment caused or did not cause an event, and the small group sizes make broad safety comparisons uncertain.

The record also reports other adverse events: 1 of 2 at-risk participants in the ranibizumab-only group, 1 of 3 in the 40% fluence combination group, and 1 of 2 in the 20% fluence combination group were affected. These figures are separate from the serious-event counts. They should not be combined or interpreted as rates of a particular event without additional details about event definitions, timing, and participant-level overlap.

The top serious adverse event term is listed as “Death of unknown origin” with 33.3%. The record does not give enough detail in the listed group figures to assign that term to a particular arm or reconcile it with the group-level death entries, which are not reported. A cause, timing, and relationship to treatment are not reported in the registry record. These summaries therefore describe what was entered, not a causal safety conclusion.

13. What the Result Does, and Does Not, Mean

The posted result means that the registry records zero participants meeting the titled visual-acuity gain-or-loss threshold in each listed treatment group at 12 months. It is a count-based observation from a study with enrollment listed as 7. The record does not provide a formal treatment-effect estimate, confidence interval, or p-value, and it marks the two-arm binary comparison as unavailable because values are missing or not estimable.

This pattern does not show that the treatment strategies are equivalent. Equivalence requires a prespecified margin and an analysis that estimates uncertainty around the difference; those details are not reported in the registry record. Nor do zero recorded events establish that the underlying probability of crossing the threshold is zero. Sparse observations can be compatible with a range of possible underlying outcomes.

The endpoint is threshold-based and does not capture all visual-acuity changes. A participant might have a change that does not meet the gain-or-loss criterion, and the record does not report individual letter changes or separate gain and loss counts. Therefore, the result should not be translated into a claim that vision was unchanged. In addition, the endpoint title mentions 6 months, but the registry description says ETDRS visual acuity was not measured at that time; the posted result pertains to the 12-month measure.

The record does not explain why the trial was terminated or whether all intended observations were collected. It also does not report how missing data were handled, what analysis population was used beyond “As per subjects participated,” or what statistical plan governed the comparison. These limitations mean that the result has little power to distinguish a real treatment difference from sampling variation. It should be read as a limited account of the posted outcome counts, not as a definitive assessment of benefit, lack of benefit, or comparative safety.

14. Why This Trial Matters Statistically

Statistically, the LUV Trial is a useful example of the difference between recording an outcome and establishing a comparative result. The registry includes group-level counts for a clinically framed threshold outcome, but the sparse counts do not yield a reported treatment-effect estimate or an interpretable formal comparison. This distinction matters: a numerical result can be present without providing enough information to support a precise inference.

The record also illustrates why endpoint definitions and timing need to be read together. The title refers to 6 and 12 months, while the description says that ETDRS visual acuity was not measured at 6 months. A reader who relies only on the title could misunderstand which time point contributes to the posted result. Clear alignment of endpoint titles, measurement schedules, and analysis results is important for transparent reporting.

For clinical researchers, the study underscores the statistical constraints created by very small groups and a terminated trial. Sparse binary outcomes can make comparative estimates difficult or impossible to obtain, and a lack of a reported test is not the same as evidence of no difference. Likewise, planning illustrations based on an observed effect cannot substitute for the original design rationale or for analysis of the completed study.

The safety record provides a further reporting lesson. Group-level serious and other adverse-event counts are informative as descriptions, but the serious-event term list does not give enough detail to link every term to an arm, timing, or treatment relationship. Complete definitions and context are needed before safety summaries can support comparisons.

The value of this record is therefore principally methodological: it makes visible the limits of inference when enrollment is small, follow-up and analysis details are incomplete, and results are reported as counts without uncertainty estimates. Those limitations should remain central when interpreting the treatment comparison.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry status is terminated, but the reason is not reported in the registry record. Enrollment is listed as 7, and the group sizes are small. The record does not describe whether the planned recruitment target was reached, whether follow-up was complete, or whether termination affected endpoint collection. Without those details, it is difficult to determine how representative the posted data are of the intended study population.

The endpoint title and description do not align fully: the title refers to ETDRS visual acuity at 6 and 12 months, while the description says it was not measured by ETDRS at 6 months. The primary result is a count for the 12-month threshold, not a full account of visual-acuity change. Separate gains and losses, continuous letter changes, and participant-level outcome data are not reported in the registry record.

The record does not report randomization methods, concealment, assessor masking, detailed eligibility criteria, baseline characteristics, adherence, withdrawals, missing-data handling, or the statistical analysis plan. Although masking is listed as none, the record does not clarify whether outcome assessment was otherwise protected from knowledge of assigned treatment. The analysis population is described only as “As per subjects participated.”

No primary comparative estimate, confidence interval, p-value, or analysis is reported, and the binary comparison is identified as not estimable. The record also lacks details about multiplicity and the rationale for sample size. Safety summaries have limited context about event definitions, timing, attribution, and the listed death term. These omissions constrain both the precision and the scope of conclusions that can be drawn.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration — NCT00423189.
• Registry record last updated 2016-03-04; status last verified 2016-02.
• Results first posted 2016-03-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The LUV Trial is registered as a Phase IV, randomized, parallel-group study with no masking, comparing ranibizumab alone with ranibizumab combined with reduced-fluence verteporfin PDT in age-related macular degeneration. The record lists enrollment as 7, a start of 2007-01, primary completion of 2009-01, and status as terminated.

The primary endpoint concerns a gain or loss of >15 letters at 12 months. The registry says ETDRS visual acuity was not measured at 6 months. The posted event count is zero in each listed group, but no comparative estimate or uncertainty interval is reported, and the binary comparison is marked unavailable or not estimable.

The record lists secondary outcomes concerning injections, OCT macular thickness, choroidal perfusion, and safety. It does not report the termination reason, detailed analysis methods, missing-data handling, or a statistical analysis plan. The outcome counts are descriptive and do not establish equivalence or a definitive treatment effect.